Put a clear name to the medicine.
Get the product name and the purpose clear before comparing offers.
What the medicine does
The Zepbound label describes tirzepatide as acting on hormones, the body’s chemical messages, that help control appetite and blood sugar.
The name of a medicine tells only part of the story; the reason it is offered matters too.
The brand names have different approved uses
Tirzepatide (Mounjaro) has approval to treat type 2 diabetes, which affects blood sugar. This is the use described in its label checked September 26, 2026.
It also has approval to lower the chance of major heart problems in adults with that condition who face high heart risk.
Mounjaro does not have an approval for weight loss, as of that check.
Tirzepatide (Zepbound) has approval for managing weight over the long term in adults with obesity, or in overweight adults who have a health problem linked to weight. Obesity means a high level of body fat. This is the use described in its label checked September 26, 2026.
That use is alongside a diet with fewer calories, the energy in food, and more physical activity.
Its approval also covers obstructive sleep apnea of moderate to severe degree for adults who have obesity. This condition means breathing repeatedly becomes blocked during sleep.
What “compounded” means
Compounding means making or changing medicine to suit one patient’s needs, in place of supplying a drug company’s finished product.
The Food and Drug Administration (FDA), the U.S. agency that checks medicines, has not approved compounded medicines, as checked September 26, 2026.
The agency does not assess a compounded medicine’s safety, quality or benefit before it is sold.
Compounding is not automatically unlawful; it may address a patient’s need that an approved medicine leaves unmet.
Tirzepatide was no longer on the national shortage list in the FDA records checked September 26, 2026.
By September 26, 2026, the FDA had ended its temporary policy of holding off action over certain copying that depended on tirzepatide being in shortage.
For regular pharmacies, the law limits routinely copying medicines that drug companies already sell. It allows an exception when the prescriber decides a change would make an important difference for a named patient.
A price saving by itself is not enough for that exception.
A patient’s allergy to a colouring ingredient is an example of a need that can lead to a medicine being made differently.
If a compounded product is proposed, ask what need the change meets in your case and who will make it. Keep that discussion separate from the price.